Literature DB >> 12731004

New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes.

Catherine M Dalton1, Peter A Brex, Katherine A Miszkiel, Kryshani Fernando, David G MacManus, Gordon T Plant, Alan J Thompson, David H Miller.   

Abstract

In clinically isolated syndromes, the new McDonald criteria for multiple sclerosis diagnosis require new gadolinium-enhancing lesions for dissemination in time at a 3-month follow-up magnetic resonance imaging scan. In a cohort of 56 patients, these criteria were specific (95%) but less sensitive (58%) for clinically definite multiple sclerosis at 3 years. If new T2 lesions were allowed as an alternative for dissemination in time, sensitivity increased (74%) with maintained specificity (92%), enabling an accurate diagnosis of multiple sclerosis in more patients.

Entities:  

Mesh:

Year:  2003        PMID: 12731004     DOI: 10.1002/ana.10580

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

Review 1.  Loss of vision: imaging the visual pathways.

Authors:  H R Jäger
Journal:  Eur Radiol       Date:  2005-01-26       Impact factor: 5.315

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 3.  Multiple sclerosis: new insights and trends.

Authors:  M Inglese
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

4.  Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis.

Authors:  Tijmen Korteweg; Bernard M J Uitdehaag; Dirk L Knol; Robin H M Smithuis; Paul R Algra; Cees de Vries; Peter A Poppe; Jan-Hein T M van Waesberghe; Elisabeth Bergers; Geert J Lycklama à Nijeholt; Chris H Polman; Frederik Barkhof
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 5.315

5.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

Review 6.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Authors:  J H Simon; D Li; A Traboulsee; P K Coyle; D L Arnold; F Barkhof; J A Frank; R Grossman; D W Paty; E W Radue; J S Wolinsky
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

8.  Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach.

Authors:  Martin Stangel; Ralf Gold; Achim Gass; Judith Haas; Stefan Jung; Wolfgang Elias; Uwe K Zettl
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

9.  FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla.

Authors:  Rainald Bachmann; Ralf Reilmann; Wolfram Schwindt; Harald Kugel; Walter Heindel; Stefan Krämer
Journal:  Eur Radiol       Date:  2005-12-20       Impact factor: 5.315

Review 10.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.